Haemonetics Corporation (HAE) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.42%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-27..
- Stock-based compensation / revenue · 12 months: Value 2.50%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-27..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.42% | Research and development expense / revenue. Period ending 2026-06-27. $59.70M ÷ $1.35B × 100 ≈ 4.42% |
| Stock-based compensation / revenue · 12 months | 2.50% | Share-based compensation / revenue. Period ending 2026-06-27. $33.83M ÷ $1.35B × 100 ≈ 2.50% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 59.70M USD | Research and Development Expense |
| Revenue | 1.35B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 33.83M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 160.32M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $59.70M | $1.35B | $33.83M | $160.32M | (m) | 4.42% | 2.50% | (m) | (m) |
| 2026-03-28 | $59.77M | $1.33B | $33.83M | $156.73M | (m) | 4.48% | 2.54% | (m) | (m) |
| 2025-12-27 | $63.63M | $1.32B | $31.64M | $251.09M | (m) | 4.83% | 2.40% | (m) | (m) |
| 2025-09-27 | $65.27M | $1.33B | $32.05M | $242.73M | (m) | 4.92% | 2.41% | (m) | (m) |
| 2025-06-28 | $64.53M | $1.35B | $31.32M | $235.93M | (m) | 4.79% | 2.33% | (m) | (m) |
| 2025-03-29 | $62.72M | $1.36B | $29.64M | $221.82M | (m) | 4.61% | 2.18% | (m) | (m) |
| 2024-12-28 | $62.66M | $1.37B | $30.12M | $180.43M | (m) | 4.56% | 2.19% | (m) | (m) |
| 2024-09-28 | $60.10M | $1.36B | $29.12M | $167.37M | (m) | 4.42% | 2.14% | (m) | (m) |
| 2024-06-29 | $56.24M | $1.33B | $28.97M | $150.98M | (m) | 4.22% | 2.17% | (m) | (m) |
| 2024-03-30 | $54.44M | $1.31B | $28.33M | $164.88M | (m) | 4.16% | 2.16% | (m) | (m) |
| 2023-12-30 | $54.22M | (m) | $27.97M | $170.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $53.65M | (m) | $28.24M | $167.50M | (m) | (m) | (m) | (m) | (m) |
| 2023-07-01 | $51.88M | (m) | $27.27M | $178.93M | (m) | (m) | (m) | (m) | (m) |
| 2023-04-01 | $50.13M | (m) | $25.58M | $156.03M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $47.70M | (m) | $23.62M | $139.98M | (m) | (m) | (m) | (m) | (m) |
| 2022-10-01 | $45.05M | (m) | $22.59M | $132.35M | (m) | (m) | (m) | (m) | (m) |
| 2022-07-02 | $45.00M | (m) | $22.83M | $110.13M | (m) | (m) | (m) | (m) | (m) |
| 2022-04-02 | $46.80M | (m) | $24.36M | $80.75M | (m) | (m) | (m) | (m) | (m) |
| 2022-01-01 | $44.43M | (m) | $26.37M | $40.38M | (m) | (m) | (m) | (m) | (m) |
| 2021-10-02 | $41.90M | (m) | $26.20M | $45.15M | (m) | (m) | (m) | (m) | (m) |
| 2021-07-03 | $37.81M | (m) | $26.18M | $79.42M | (m) | (m) | (m) | (m) | (m) |
| 2021-04-03 | $32.86M | (m) | $25.52M | $89.75M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-26 | $30.99M | (m) | $23.80M | $136.93M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-26 | $30.49M | (m) | $22.84M | $137.41M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-27 | $31.15M | (m) | $21.89M | $128.37M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-28 | $30.88M | (m) | $20.45M | $103.35M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-28 | $30.66M | (m) | $19.50M | $101.20M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-28 | $32.63M | (m) | $18.96M | $88.61M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-29 | $33.80M | (m) | $18.54M | $64.95M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-30 | $35.71M | (m) | $17.19M | $83.55M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-29 | $38.05M | (m) | $18.41M | $73.96M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-29 | $41.50M | (m) | $16.79M | $46.66M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $40.44M | (m) | $15.06M | $44.84M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $39.23M | (m) | $13.03M | $56.16M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-30 | $37.46M | (m) | $9.90M | $-15.62M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $33.50M | (m) | $9.11M | $4.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-07-01 | $34.31M | (m) | $8.65M | $5.11M | (m) | (m) | (m) | (m) | (m) |
| 2017-04-01 | $37.56M | (m) | $9.15M | $-19.38M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $39.38M | (m) | $7.36M | $32.58M | (m) | (m) | (m) | (m) | (m) |
| 2016-10-01 | $41.86M | (m) | $7.30M | $-49.81M | (m) | (m) | (m) | (m) | (m) |
| 2016-07-02 | $45.08M | (m) | $5.63M | $-55.43M | (m) | (m) | (m) | (m) | (m) |
| 2016-04-02 | $44.97M | (m) | $6.95M | $-43.94M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-26 | $51.04M | (m) | (m) | $-26.85M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-26 | $50.74M | (m) | (m) | $52.58M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-27 | $50.13M | (m) | (m) | $45.81M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-28 | $54.19M | $910.37M | $14.10M | $40.54M | (m) | 5.95% | 1.55% | (m) | (m) |
| 2014-12-27 | $50.80M | (m) | (m) | $41.65M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-27 | $54.36M | (m) | $13.60M | $41.25M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-28 | $58.37M | (m) | $13.56M | $52.27M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-29 | $54.20M | $938.51M | $13.08M | $47.33M | (m) | 5.78% | 1.39% | (m) | (m) |
| 2013-12-28 | $53.94M | (m) | $12.70M | $52.39M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-28 | $50.31M | (m) | (m) | $50.28M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-29 | $46.19M | (m) | $11.56M | $36.75M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-30 | $44.39M | $891.99M | $10.97M | $56.44M | (m) | 4.98% | 1.23% | (m) | (m) |
| 2012-12-29 | $39.43M | (m) | $10.49M | $59.69M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-29 | $38.08M | (m) | $9.60M | $69.26M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $37.60M | (m) | $9.30M | $77.93M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $36.80M | $727.84M | $9.29M | $88.76M | (m) | 5.06% | 1.28% | (m) | (m) |
| 2011-12-31 | $36.98M | (m) | $9.39M | $96.69M | (m) | (m) | (m) | (m) | (m) |
| 2011-10-01 | $35.74M | (m) | $11.42M | $99.93M | (m) | (m) | (m) | (m) | (m) |
| 2011-07-02 | $33.34M | (m) | $11.01M | $110.27M | $-41.00K | (m) | (m) | (m) | Reported |
| 2011-04-02 | $32.66M | (m) | $10.81M | $110.55M | $6.00K | (m) | (m) | 18424.67× | Reported |
| 2011-01-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-10-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-04-03 | $26.38M | (m) | $10.27M | $83.28M | $742.00K | (m) | (m) | 112.24× | Reported |
| 2009-12-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-28 | $23.86M | (m) | $10.18M | $85.57M | $64.00K | (m) | (m) | 1336.98× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |